Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo

Molecular Metabolism

Volumn 3, Issue 6, 2014, Pages 630-641

  Kleinert, Maximilian ^a   Sylow, Lykke ^a   Fazakerley, Daniel J ^b   Krycer, James R ^b,f   Thomas, Kristen C ^b   Oxbøll, Anne Julie ^a   Jordy, Andreas B ^a   Jensen, Thomas E ^a   Yang, Guang ^b   Schjerling, Peter ^d   Kiens, Bente ^a   James, David E ^b,c   Ruegg, Markus A ^e   Richter, Erik A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Glucose uptake; Glycolysis; Metabolism; MTORC2; Rictor; Skeletal muscle

Indexed keywords

AZD 8055; GLUCOSE TRANSPORTER 4; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; RAPAMYCIN; RICTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MOUSE; MUSCLE CELL; MUSCLE METABOLISM; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLEUS MUSCLE;

MUS;

EID: 84906244306     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.06.004     Document Type: Article

References (49)

1. Laplante M., Sabatini D. MTOR signaling in growth control and disease. Cell 2012, 149:274-293.
2. Hagiwara A., Cornu M., Cybulski N., Polak P., Betz C., Trapani F., et al. Hepatic MTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metabolism 2012, 15:725-738.
3. Kumar A., Lawrence J.C., Jung D.Y., Ko H.J., Keller S.R., Kim J.K., et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010, 59:1397-1406.
4. Yuan M., Pino E., Wu L., Kacergis M., Soukas A.A. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (MTOR) complex 2. Journal of Biological Chemistry 2012, 287:29579-29588.
5. Kocalis H.E., Hagan S.L., George L., Turney M.K., Siuta M.A., Laryea G.N., et al. Rictor/MTORC2 facilitates central regulation of energy and glucose homeostasis. Molecular Metabolism 2014, 3:394-407.
6. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-MTOR complex. Science 2005, 307:1098-1101.
7. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of MTOR inhibitors. Nature Reviews Drug Discovery 2011, 10:868-880.
8. Selman C., Tullet J.M.A., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
9. Anisimov V.N., Zabezhinski M.A., Popovich I.G., Piskunova T.S., Semenchenko A.V., Tyndyk M.L., et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011, 10:4230-4236.
10. Chen C., Liu Y., Liu Y., Zheng P. MTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Science Signalling 2009, 2:ra75.
11. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
12. Neff F., Flores-Dominguez D., Ryan D.P., Horsch M., der S., Adler T., et al. Rapamycin extends murine lifespan but has limited effects on aging. The Journal of Clinical Investigation 2013, 123:3272-3291.
13. Miller R.A., Harrison D.E., Astle C.M., Baur J.A., Boyd A.R., de Cabo R., et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2011, 66A:191-201.
14. Chang G.R., Wu Y.Y., Chiu Y.S., Chen W.Y., Liao J.W., Hsu H.M., et al. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic & Clinical Pharmacology & Toxicology 2009, 105:188-198.
15. Fang Y., Westbrook R., Hill C., Boparai R., Arum O., Spong A., et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metabolism 2013, 17:456-462.
16. Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., et al. MTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57:945-957.
17. Houde V.P., Brûlé S., Festuccia W.T., Blanchard P.G., Bellmann K., Deshaies Y., et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010, 59:1338-1348.
18. Yang S.B., Lee H., Young D., Tien A.C., Rowson-Baldwin A., Shu Y., et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. Journal of Molecular Medicine 2012, 90:575-585.
19. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., et al. Rapamycin-induced insulin resistance is mediated by MTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
20. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of MTORC1. Journal of Biological Chemistry 2009, 284:8023-8032.
21. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits MTORC2 assembly and Akt/PKB. Molecular Cell 2006, 22:159-168.
22. Bentzinger C.F., Romanino K., Cloetta D., Lin S., Mascarenhas J.B., Oliveri F., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metabolism 2008, 8:411-424.
23. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Research 2010, 70:288-298.
24. 13C]Glucose and endogenous energy substrate oxidation during prolonged treadmill running. Journal of Applied Physiology 2002, 92:1255-1260.
25. Jensen T.E., Rose A.J., Jørgensen S.B., Brandt N., Schjerling P., Wojtaszewski J.F.P., et al. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. American Journal of Physiology - Endocrinology and Metabolism 2007, 292:E1308-E1317.
26. Wang Q., Khayat Z., Kishi K., Ebina Y., Klip A. GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay. FEBS Letters 1998, 427:193-197.
27. Somwar R., Sweeney G., Ramlal T., Klip A. Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clinical Therapeutics 1998, 20:125-140.
28. Ploug T., Wojtaszewski J., Kristiansen S., Hespel P., Galbo H., Richter E.A. Glucose transport and transporters in muscle giant vesicles: differential effects of insulin and contractions. American Journal of Physiology - Endocrinology and Metabolism 1993, 264:E270-E278.
29. Prabhu A.V., Krycer J.R., Brown A.J. Overexpression of a key regulator of lipid homeostasis, Scap, promotes respiration in prostate cancer cells. FEBS Letters 2013, 587:983-988.
30. Maarbjerg S.J., Jorgensen S.B., Rose A.J., Jeppesen J., Jensen T.E., Treebak J.T., et al. Genetic impairment of AMPKalpha2 signaling does not reduce muscle glucose uptake during treadmill exercise in mice. American Journal of Physiology - Endocrinology and Metabolism 2009, 297:E924-E934.
31. Lowry O.H., Passonneau J.V. A flexible system of enzymatic analysis 1972, Academic Press, New York.
32. Humphrey S.J., James D.E. Uncaging Akt. Science Signalling 2012, 5:e20.
33. Miinea C.P., Sano H., Kane S., Sano E., Fukuda M., Peranen J., et al. AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain. Biochemical Journal 2005, 391:87-93.
34. Sano H., Kane S., Sano E., Mîinea C.P., Asara J.M., Lane W.S., et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. Journal of Biological Chemistry 2003, 278:14599-14602.
35. Masui K., Tanaka K., Akhavan D., Babic I., Gini B., Matsutani T., et al. MTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of C-Myc. Cell Metabolism 2013, 18:726-739.
36. Kumar A., Harris T.E., Keller S.R., Choi K.M., Magnuson M.A., Lawrence J.C. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Molecular and Cellular Biology 2008, 28:61-70.
37. Tremblay F., Gagnon A., Veilleux A., Sorisky A., Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005, 146:1328-1337.
38. Tzatsos A., Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent MTOR-mediated insulin receptor substrate 1 phosphorylation. Molecular and Cellular Biology 2006, 26:63-76.
39. Krebs M., Brunmair B., Brehm A., Artwohl M., Szendroedi J., Nowotny P., et al. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007, 56:1600-1607.
40. Miller A.M., Brestoff J.R., Phelps C.B., Berk E.Z., Reynolds T.H. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of Ob/Ob mice. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2008, 295:R1431-R1438.
41. Polak P., Cybulski N., Feige J.N., Auwerx J., Rüegg M.A., Hall M.N. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metabolism 2008, 8:399-410.
42. Mora A., Davies A.M., Bertrand L., Sharif I., Budas G.R., Jovanovic S., et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. The EMBO Journal 2003, 22:4666-4676.
43. Mora A., Lipina C., Tronche F., Sutherland C., Alessi D.R. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochemical Journal 2005, 385:639-648.
44. Zhao X., Lu S., Nie J., Hu X., Wen L., Wu X., et al. Phosphoinositide-dependent kinase and MTORC2 synergistically maintain postnatal heart growth and heart function in mice. Molecular and Cellular Biology 2014, 11:1966-1975.
45. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., et al. Ablation in mice of the MTORC components raptor, rictor, or MLST8 reveals that MTORC2 is required for signaling to Akt-FOXO and PKCa, but not S6K1. Developmental Cell 2006, 11:859-871.
46. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-MTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
47. Shiota C., Woo J.T., Lindner J., Shelton K.D., Magnuson M.A. Multiallelic disruption of the rictor gene in mice reveals that MTOR complex 2 is essential for fetal growth and viability. Developmental Cell 2006, 11:583-589.
48. Ye L., Varamini B., Lamming D.W., Sabatini D.M., Baur J.A. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of MTORC1 and MTORC2. Frontiers in Genetics 2012, 3.
49. Moore M.C., Coate K.C., Winnick J.J., An Z., Cherrington A.D. Regulation of hepatic glucose uptake and storage in vivo. Advances in Nutrition: An International Review Journal 2012, 3:286-294.